She joins Scholar Rock’s Executive Team ... she had roles of increasing responsibility at Mersana Therapeutics, Shire, and Boston Scientific. She graduated from Ithaca College with a degree ...

Ms. Wyman joins Scholar Rock from Generate ... she had roles of increasing responsibility at Mersana Therapeutics, Shire, and Boston Scientific. She graduated from Ithaca College with a degree ...

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and Company ("Lilly"). This collaboration focuses on ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edwards Lifesciences (EW – Research Report), Arvinas Holding ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company, has appointed Lisa Wyman as the Chief Technical and ...

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly ...

she had roles of increasing responsibility at Mersana Therapeutics, Shire, and Boston Scientific. She graduated from Ithaca College with a degree in biology and earned a master’s degree in engineering ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

KBC Group NV purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 3,020 shares of the company’s ...

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...